Table 4 Serious adverse effects
Event | MSC group (N = 99) | Control group (N = 99) |
|---|---|---|
Any adverse event | 41 (41.4%) | 44 (44.4%) |
Hematologica | 9 (9.1%) | 13 (13.1%) |
 Platelets decreased | 6 (6.1%) | 8 (8.1%) |
 Platelet and neutrophil both decreased | 3 (3.0%) | 5 (5.1%) |
Skinb | 0 (0%) | 1 (1.0%) |
Gastrointestinalb | 4 (4.0%) | 5 (5.1%) |
Hepatobilinary or pancreaticb | 2 (2.0%) | 2 (2.0%) |
Cardiac (heart failure) | 4 (4.0%) | 6 (6.1%) |
Renal or genitourinary (cystitis non-infective) | 4 (4.0%) | 5 (5.1%) |
Vascular (thrombotic microangiopathy) | 0 (0%) | 1 (1.0%) |
Infections | 12 (12.1%) | 16 (16.2%) |
Secondary malignant disease | 0 (0%) | 0 (0%) |